Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment. | Int. J. Med. Sci. 2009 6 338 International Journal of Medical Sciences 2009 6 6 338-347 Ivyspring International Publisher. All rights reserved Research Paper High-Resolution Flow Cytometry a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment Klaus Braun1 H Volker Ehemann2 Manfred Wiessler1 Ruediger Pipkorn3 Bernd Didinger4 Gabriele Mueller5 Waldemar Waldeck5 1. German Cancer Research Center Dept. of Medical Physics in Radiooncology INF 280 D-69120 Heidelberg Germany 2. University of Heidelberg Institute of Pathology INF 220 D-69120 Heidelberg Germany 3. German Cancer Research Center Central Peptide Synthesis Unit INF 580 D-69120 Heidelberg Germany 4. Radiation Oncology University of Heidelberg INF 400 D-69120 Heidelberg Germany 5. German Cancer Research Center Division of Biophysics of Macromolecules INF 580 D-69120 Heidelberg Germany The authors contributed by equal parts to this work H Correspondence to Dr. Klaus Braun Medical Physics in Radiology Deutsches Krebsforschungszentrum DKFZ Im Neuenherner Feld 280 D-69120 Heidelberg Germany. Tel 49 6221 42 2495 Fax 49 6221 42 3326. kbraun@dkfz.de Received 2009.08.17 Accepted 2009.11.16 Published 2009.11.18 Abstract If metastatic prostate cancer gets resistant to antiandrogen therapy there are few treatment options because prostate cancer is not very sensitive to cytostatic agents. Temozolomide TMZ as an orally applicable chemotherapeutic substance has been proven to be effective and well tolerated with occasional moderate toxicity especially for brain tumors and an application to prostate cancer cells seemed to be promising. Unfortunately TMZ was inefficient in the treatment of symptomatic progressive hormone-refractory prostate cancer HRPC . The reasons could be a low sensitivity against TMZ the short plasma half-life of TMZ non-adapted application regimens and additionally the aneuploid DNA content of prostate cancer cells suggesting different sensitivity against .